The Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) drugs in development market research report provides comprehensive information on the therapeutics under development for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) and features dormant and discontinued products.
GlobalData tracks 35 drugs in development for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) by 27 companies/universities/institutes. The top development phase for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) is phase ii with 13 drugs in that stage. The Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline has 34 drugs in development by companies and one by universities/ institutes. Some of the companies in the Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline products market are: Pharma Mar, Jiangsu Hengrui Medicine and Ipsen.
The key targets in the Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline products market include Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2), Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), and Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1).
See Also:
The key mechanisms of action in the Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline product include Cytotoxic To Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2) with nine drugs in Phase III. The Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline products include 11 routes of administration with the top ROA being Intravenous and seven key molecule types in the Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline products market including Small Molecule, and Synthetic Peptide.
Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) overview
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous group of neoplasms that originate from neuroendocrine cells in the gastrointestinal tract and pancreas. These cells produce hormones that regulate various functions in the body. GEP-NETs can be classified as functional or non-functional, depending on whether they secrete excess hormones or not. Functional GEP-NETs can cause various syndromes, such as carcinoid syndrome, Zollinger-Ellison syndrome, or Verner-Morrison syndrome, depending on the type of hormone produced. Non-functional GEP-NETs may not cause any symptoms until they grow large or metastasize to other organs. The diagnosis of GEP-NETs is based on histopathology, immunohistochemistry, and hormonal assays. The treatment options include surgery, chemotherapy, radiotherapy, somatostatin analogues, peptide receptor radionuclide therapy, and targeted therapy. The prognosis of GEP-NETs depends on several factors, such as the tumor grade, stage, location, and functionality.
For a complete picture of Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
